Advancing First-in-Class & Best-in-Class Multispecific ADC & T-Cell Engager Therapies
- Leveraging proprietary target mining and drug discovery platforms to enable first-in-class (FIC) and best-in-class (BIC) multispecific biologic development
- Design and development strategy behind multispecific ADC and T-cell engager programs, including differentiation within competitive target landscapes
- Pipeline progression and strategic collaborations supporting clinical translation of multispecific platforms